Frontiers Lu-177-PSMA dosimetry for kidneys and tumors based on

Feasibility of single time point image-based dosimetry using prior

PDF) Towards Single Time Point Image-Based Dosimetry of 177 Lu

Hotspots and frontiers in PSMA research for prostate cancer: a

Frontiers Current role of prostate-specific membrane antigen-based imaging and radioligand therapy in castration-resistant prostate cancer

Frontiers Towards Routine Clinical Use of Dosimetry in [177Lu]Lu

Investigation of image-based lesion and kidney dosimetry protocols

Lutetium-177 prostate-specific membrane antigen (PSMA

Frontiers 177Lu-PSMA-I&T Radioligand Therapy for Treating

SNMMI 2023: Tumour-to-Kidney Ratio on Pre-Therapeutic PSMA-PET-CT

Pharmaceuticals, Free Full-Text

Frontiers Lu-177-PSMA dosimetry for kidneys and tumors based on